clinical trial

Seres Therapeutics swung to $5.7M 2025 profit from $125.8M loss, boosted by Nestlé VOWST sale, with $45.8M cash funding ops through Q3 2026.

Gyre Therapeutics posts 10% FY2025 revenue growth to $116.6M, guides 2026 lower due to regulatory prioritization and Cullgen acquisition for TPD expansion.

Soleno Therapeutics faces class action lawsuit alleging material safety concerns about DCCR drug were hidden from investors. Lead plaintiff deadline is May 5, 2026.

Tevogen Bio ($TVGN) expands T-cell therapy coverage to 65% of U.S. population and pursues digital care platform acquisition to advance Long COVID treatment.

Tempest Therapeutics partners with Cincinnati Children's for TPST-2003 manufacturing, targeting U.S. registrational study launch in 2026 following strong interim trial results.

Class action lawsuit filed against Soleno Therapeutics for allegedly failing to disclose material safety concerns about its DCCR product. Investors can apply as lead plaintiff by May 5, 2026.

Protara Therapeutics reported $57.4M full-year 2025 loss while unveiling promising 68% response rate for TARA-002 in bladder cancer trial with funding extending to 2028.

$SLNO faces securities lawsuit alleging misleading safety claims for hyperphagia drug VYKAT XR. Stock crashed 40% after short seller report and management admissions of launch disruptions.

Class action lawsuit filed against REGENXBIO alleging false statements about RGX-111 gene therapy. Covers investors from Feb 2022 to Jan 2026; lead plaintiff deadline April 14.

AbbVie reports Phase 1 data for obesity treatment ABBV-295, showing 7.75%-9.79% weight loss. Stock declined despite positive results amid broader market pressure.

Anixa Biosciences secures patent protection in South Korea for breast cancer vaccine technology, advancing its IP portfolio as Phase 1 trial shows 74% immune response rate.

Editas Medicine reported Q4 2025 net loss of $5.6M, down 88% YoY. Lead CRISPR therapy EDIT-401 shows >90% LDL-C reduction; IND submission expected mid-2026.

Pfizer wins NMPA approval for weight-loss drug ecnoglutide in China, achieving 15.4% average weight loss in trials, intensifying competition as Novo Nordisk's Wegovy faces patent expiry.

Novo Nordisk's Kagrama showed weaker weight-loss results than Eli Lilly's Zepbound in 84-week trial, pressuring obesity growth forecasts.

Theravance Biopharma shares plummet 27% after ampreloxetine fails Phase 3 trial; company cuts workforce 50% and reduces expenses 60%.

EMA committee endorses mavorixafor (XOLREMDI) for WHIM syndrome treatment, marking first approved therapy in Europe. Final Commission approval expected Q2 2026.

Anteris secures $320M funding to advance DurAVR heart valve through global trials, with FDA approval and increased clinical development spending.

ImmunityBio completed Phase 3 cancer trial enrollment ahead of schedule with strong 85% response rates. Anktiva sales surged 750% year-over-year, hitting $38.29M in revenue.

Soligenix wins EMA orphan drug designation backing for SGX945 treating Behçet's Disease, following positive Phase 2a results and prior FDA support.

TScan completes Phase 1 trial enrollment and receives FDA clearance for two allogeneic cell therapy candidates, advancing its pipeline toward pivotal studies in 2026.